OGEN ORAGENICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ORAGENICS INC reported revenue of n/a, net income of −$2.53M and diluted EPS of −$0.57; for the fiscal year ended December 2025 revenue was n/a.
OGEN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$9.36M, net income −$984M (margin n/a), EPS −$4.56
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$10.6M, net income −$1.06B (margin n/a), EPS −$47.88
- Fiscal year ended Dec 2023: revenue $37.7K, gross profit n/a, operating income −$20.9M, net income −$20.7M (margin -54858.1%), EPS −$9.18
- Fiscal year ended Dec 2022: revenue $132K, gross profit n/a, operating income −$14.4M, net income −$14.3M (margin -10864.0%), EPS −$7.11
- Fiscal year ended Dec 2021: revenue $87.0K, gross profit n/a, operating income −$15.8M, net income −$15.7M (margin -18062.0%), EPS −$0.14
OGEN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$2.53M, EPS −$0.57
- Quarter ended Mar 31, 2026: revenue n/a, net income −$2.20M, EPS −$0.51
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$977M, EPS $4.15
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.07M, EPS −$1.96
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.27M, EPS −$3.10
- Quarter ended Mar 31, 2025: revenue n/a, net income −$2.22M, EPS −$3.65
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$1.05B, EPS −$20.59
- Quarter ended Sep 30, 2024: revenue n/a, net income −$2.46M, EPS −$11.32
- Quarter ended Jun 30, 2024: revenue n/a, net income −$2.31M, EPS −$15.27
- Quarter ended Mar 31, 2024: revenue n/a, net income −$2.45M, EPS −$0.70
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0, net income −$12.7M, EPS −$5.41
- Quarter ended Sep 30, 2023: revenue $7.47K (down 91.3% year over year), net income −$2.01M, EPS −$0.85
- Quarter ended Jun 30, 2023: revenue $13.2K (down 56.7% year over year), net income −$3.05M, EPS −$1.51
- Quarter ended Mar 31, 2023: revenue $17.0K (up 12.9% year over year), net income −$2.84M, EPS −$1.41
- Quarter ended Dec 31, 2022 (from the annual report): revenue $0, net income −$2.24M, EPS n/a
- Quarter ended Sep 30, 2022: revenue $86.0K, net income −$3.87M, EPS −$1.99
- Quarter ended Jun 30, 2022: revenue $30.4K, net income −$3.59M, EPS −$1.85
- Quarter ended Mar 31, 2022: revenue $15.1K, net income −$4.59M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$2.29M, EPS −$0.02
- Quarter ended Sep 30, 2021: revenue n/a, net income −$4.38M, EPS −$0.04
OGEN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$9.25M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$8.60M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$7.29M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$15.2M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$13.5M, share buybacks n/a
OGEN balance sheet
- Jun 30, 2026: cash $3.86M, total assets $5.49M, total liabilities $1.82M, shareholders' equity $3.67M
- Mar 31, 2026: cash $6.11M, total assets $7.49M, total liabilities $1.31M, shareholders' equity $6.18M
- Dec 31, 2025: cash $4.40M, total assets $10.1M, total liabilities $1.79M, shareholders' equity $8.28M
- Sep 30, 2025: cash $11.4M, total assets $12.7M, total liabilities $2.87M, shareholders' equity $9.83M
- Jun 30, 2025: cash $1.97M, total assets $2.14M, total liabilities $4.27M, shareholders' equity −$2.13M
- Mar 31, 2025: cash $3.42M, total assets $3.87M, total liabilities $3.73M, shareholders' equity $138K
- Dec 31, 2024: cash $865K, total assets $1.47M, total liabilities $1.68M, shareholders' equity −$212K
- Sep 30, 2024: cash $3.14M, total assets $5.20M, total liabilities $2.13M, shareholders' equity $3.08M
Is OGEN profitable?
No. ORAGENICS INC lost $984M over the last four quarters.
What is OGEN's EPS?
Diluted earnings per share over the last four quarters were $1.11; −$0.57 in the latest quarter.